<DOC>
	<DOCNO>NCT01539629</DOCNO>
	<brief_summary>This 3rd phase ELEVATE study . The study collect data implant CRT-D device evaluate new feature future heart failure device .</brief_summary>
	<brief_title>ELEVATE ( Evaluation Left Ventricular Autothreshold ) 3.0</brief_title>
	<detailed_description>ELEVATE 3.0 acute , prospective , multicenter feasibility study randomize within patient test sequence pulse width . The study design characterize performance LVAT ( Left Ventricular Authothreshold ) feature .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients age 18 , legal age give inform consent specific state national law Patients COGNIS CRTD device implant least 24 hour , without active right atrial lead Patients active LV bipolar unipolar lead Patients active RV defibrillation lead Patients willing capable participate test associate Clinical Investigation Patients COGNIS CRTD less equal one year battery life remain Patients pacemakerdependent define VVI 40 without intrinsic atrial ventricular activity Patients tolerate pacing pause 6 second Patients preexist unipolar pacemaker Patients unable unwilling maintain supine sit position 2050 minute Patients enrol concurrent study , without Boston Scientific CRM write approval Women pregnant ; woman childbearing potential must negative pregnancy test within 7 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Autothreshold</keyword>
	<keyword>Pacing</keyword>
	<keyword>CRT-D recipient</keyword>
	<keyword>Left Ventricular evoke response signal</keyword>
</DOC>